Oral Recombinant Feline Interferon-Omega as an alternative immune modulation therapy in FIV positive cats: Clinical and laboratory evaluation |
| |
Authors: | S Gil RO Leal D McGahie N Sepúlveda A Duarte MMRE Niza L Tavares |
| |
Institution: | 1. Centro de Investigação Interdisciplinar em Sanidade Animal (CIISA), Faculdade de Medicina Veterinária, University of Lisbon (ULisboa), Av. Universidade Técnica, 1300 477 Lisbon, Portugal;2. Virbac, 135. rue LID – BP 27, F 06511 Carros cedex, France;3. London School of Hygiene and Tropical Medicine, Keppel Street, London WC1E7HT, United Kingdom;4. Centro de Estatística e Aplicações da Universidade de Lisboa, FCUL, Bloco C6-Piso 4 Campo Grande, 1749 016 Lisboa, Portugal |
| |
Abstract: | Recombinant-Feline Interferon-Omega (rFeIFN-ω) is an immune-modulator licensed for use subcutaneously in Feline Immunodeficiency virus (FIV) therapy. Despite oral protocols have been suggested, little is known about such use in FIV-infected cats. This study aimed to evaluate the clinical improvement, laboratory findings, concurrent viral excretion and acute phase proteins (APPs) in naturally FIV-infected cats under oral rFeIFN-ω therapy (0.1 MU/cat rFeIFN-ω PO, SID, 90 days). 11 FIV-positive cats were treated with oral rFeIFN-ω (PO Group). Results were compared to previous data from 7 FIV-positive cats treated with the subcutaneous licensed protocol (SC Group). Initial clinical scores were similar in both groups. Independently of the protocol, rFeIFN-ω induced a significant clinical improvement of treated cats. Concurrent viral excretion and APP’s variation were not significant in the PO Group. Oral rFeIFN-ω can be an effective alternative therapy for FIV-infected cats, being also an option for treatment follow-up in cats submitted to the licensed protocol. |
| |
Keywords: | Feline Immunodeficiency Virus (FIV) Recombinant-Feline Interferon Omega (rFeIFN-ω) Immune-modulation Oral therapy |
本文献已被 ScienceDirect 等数据库收录! |
|